abrdn Life Sciences Investors (HQL) Competitors $13.98 -0.01 (-0.04%) Closing price 03:58 PM EasternExtended Trading$13.98 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HQL vs. CET, GSBD, MFIC, NMFC, PFLT, BBDC, BCSF, AWF, PHK, and HQHShould you be buying abrdn Life Sciences Investors stock or one of its competitors? The main competitors of abrdn Life Sciences Investors include Central Securities (CET), Goldman Sachs BDC (GSBD), MidCap Financial Investment (MFIC), New Mountain Finance (NMFC), PennantPark Floating Rate Capital (PFLT), BARINGS BDC (BBDC), Bain Capital Specialty Finance (BCSF), AllianceBernstein Global High Income Fund (AWF), PIMCO High Income Fund (PHK), and abrdn Healthcare Investors (HQH). These companies are all part of the "financial services" industry. abrdn Life Sciences Investors vs. Its Competitors Central Securities Goldman Sachs BDC MidCap Financial Investment New Mountain Finance PennantPark Floating Rate Capital BARINGS BDC Bain Capital Specialty Finance AllianceBernstein Global High Income Fund PIMCO High Income Fund abrdn Healthcare Investors abrdn Life Sciences Investors (NYSE:HQL) and Central Securities (NYSE:CET) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability. Which has more volatility & risk, HQL or CET? abrdn Life Sciences Investors has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Central Securities has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Does the media favor HQL or CET? In the previous week, abrdn Life Sciences Investors had 3 more articles in the media than Central Securities. MarketBeat recorded 4 mentions for abrdn Life Sciences Investors and 1 mentions for Central Securities. Central Securities' average media sentiment score of 1.11 beat abrdn Life Sciences Investors' score of 0.50 indicating that Central Securities is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment abrdn Life Sciences Investors 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Central Securities 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is HQL or CET more profitable? Company Net Margins Return on Equity Return on Assets abrdn Life Sciences InvestorsN/A N/A N/A Central Securities N/A N/A N/A Which has stronger earnings & valuation, HQL or CET? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratioabrdn Life Sciences Investors-$10.95M-36.85N/AN/AN/ACentral Securities$222.17M6.47N/AN/AN/A Is HQL or CET a better dividend stock? abrdn Life Sciences Investors pays an annual dividend of $1.89 per share and has a dividend yield of 13.5%. Central Securities pays an annual dividend of $2.30 per share and has a dividend yield of 4.6%. Do institutionals and insiders hold more shares of HQL or CET? 32.2% of abrdn Life Sciences Investors shares are held by institutional investors. Comparatively, 8.7% of Central Securities shares are held by institutional investors. 10.1% of abrdn Life Sciences Investors shares are held by company insiders. Comparatively, 9.5% of Central Securities shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Summaryabrdn Life Sciences Investors and Central Securities tied by winning 4 of the 8 factors compared between the two stocks. Get abrdn Life Sciences Investors News Delivered to You Automatically Sign up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HQL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HQL vs. The Competition Export to ExcelMetricabrdn Life Sciences InvestorsFIN IndustryFinance SectorNYSE ExchangeMarket Cap$403.49M$3.87B$12.44B$20.88BDividend Yield13.85%6.44%5.56%3.59%P/E RatioN/AN/A19.5928.34Price / Sales-36.8549.3426.6654.34Price / CashN/A17.8218.7717.82Price / BookN/A1.132.244.54Net IncomeN/A$161.89M$1.01B$992.74M7 Day Performance4.49%-0.22%-0.23%0.30%1 Month Performance5.63%1.62%0.44%1.14%1 Year Performance-10.76%0.97%539.62%11.01% abrdn Life Sciences Investors Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HQLabrdn Life Sciences InvestorsN/A$13.980.0%N/A-9.5%$403.49M-$10.95M0.00N/ANews CoverageDividend CutShort Interest ↓CETCentral SecuritiesN/A$48.75-0.3%N/A+12.9%$1.41B$296.20M0.006Positive NewsGSBDGoldman Sachs BDC1.2303 of 5 stars$11.23-0.2%$10.00-10.9%-19.4%$1.28B$434.37M8.91N/AMFICMidCap Financial Investment1.7225 of 5 stars$12.62+0.2%$13.50+7.0%-6.3%$1.17B$301.78M10.18N/ANews CoverageNMFCNew Mountain Finance2.2211 of 5 stars$10.23-0.2%$10.75+5.1%-15.2%$1.09B$371.67M13.46N/ANews CoveragePositive NewsPFLTPennantPark Floating Rate Capital3.8696 of 5 stars$10.52+0.2%$10.96+4.1%-7.4%$1.04B$84.09M7.52658Short Interest ↓BBDCBARINGS BDC3.1685 of 5 stars$9.600.0%$9.67+0.7%-3.1%$1.01B$286.17M10.0026News CoveragePositive NewsBCSFBain Capital Specialty Finance2.3638 of 5 stars$15.08-0.8%$16.50+9.4%-7.3%$986M$292.65M9.091,000News CoveragePositive NewsAWFAllianceBernstein Global High Income FundN/A$11.17+0.2%N/A+1.8%$960.60MN/A0.00N/APHKPIMCO High Income FundN/A$4.88-1.7%N/A+1.1%$850.60MN/A0.00147,000News CoveragePositive NewsHQHabrdn Healthcare InvestorsN/A$15.64+0.1%N/A-13.9%$841.87MN/A0.00147,000Dividend CutShort Interest ↑ Related Companies and Tools Related Companies CET Competitors GSBD Competitors MFIC Competitors NMFC Competitors PFLT Competitors BBDC Competitors BCSF Competitors AWF Competitors PHK Competitors HQH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HQL) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding abrdn Life Sciences Investors Please log in to your account or sign up in order to add this asset to your watchlist. Share abrdn Life Sciences Investors With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access